Share

Hear EORTC Director Denis Lacombe discuss innovative forms of clinical research

As health care costs are constantly rising and governments are reforming their healthcare systems there is an urgent need to reshape the European clinical research landscape. To bridge the translational gap extensive research to understand the mechanism of the agents and of the disease has to be performed and the real benefit of drugs needs to be assessed independently. Furthermore, meaningful data for reimbursement strategies will be a major goal of future clinical trials as well.

Therefore, a new integrated model of clinical cancer research is needed to optimise the R&D process. Strategies to ensure that we can gather robust and relevant data about the effectiveness of various healthcare interventions have to be developed to provide optimal patient care within the limits of a healthcare budget.

Susen Burock, Françoise Meunier, Denis Lacombe
European Journal of Cancer 2013;49(13):2777–2783

Back to news list

Related News

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Interview of ROSC Chair, Joost Vaerhoeff

  • Independent, academic cancer trials are vital to improve patient outcomes worldwide